Misfolded α-Synuclein Assessment in the Skin and CSF by RT-QuIC in Isolated REM Sleep Behavior Disorder.
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
02 05 2023
02 05 2023
Historique:
received:
25
08
2022
accepted:
19
01
2023
pmc-release:
02
05
2024
medline:
3
5
2023
pubmed:
18
3
2023
entrez:
17
3
2023
Statut:
ppublish
Résumé
Real-time quaking-induced conversion (RT-QuIC) assay detects misfolded α-synuclein (AS) in the skin and CSF of patients with the synucleinopathies Parkinson disease and dementia with Lewy bodies. Isolated REM sleep behavior disorder (IRBD) constitutes the prodromal stage of these synucleinopathies. We aimed to compare the ability of RT-QuIC to identify AS in the skin and CSF of patients with IRBD. This was a cross-sectional study where consecutive patients with polysomnographic-confirmed IRBD and age-matched controls without RBD underwent skin biopsy and lumbar puncture the same day. Three-millimeter skin punch biopsies were obtained bilaterally in the cervical region from dorsal C7 and C8 dermatomes and in distal legs. RT-QuIC assessed AS in these 6 skin sites and the CSF. We recruited 91 patients with IRBD and 41 controls. In the skin, sensitivity to detect AS was 76.9% (95% CI 66.9-85.1), specificity 97.6% (95% CI 87.1-99.9) positive predictive value 98.6% (95% CI 91.0-99.8), negative predictive value 65.6% (95% CI 56.6-73.6), and accuracy 83.3% (95% CI 75.9-89.3). In the CSF, the sensitivity was 75.0% (95% CI 64.6-83.6), the specificity was 97.5% (95% CI 86.8-99.9), the positive predictive value was 98.5% (95% CI 90.5-99.8), the negative predictive value was 63.9% (95% CI 55.2-71.9), and the accuracy was 82.0% (95% CI 74.3-88.3). Results in the skin and CSF samples showed 99.2% agreement. Compared with negative patients, RT-QuIC AS-positive patients had a higher likelihood ratio of prodromal Parkinson disease ( Our study in IRBD shows that (1) RT-QuIC detects AS in the skin and CSF with similar high sensitivity, specificity, and agreement, (2) AS RT-QuIC positivity is associated with supportive features and biomarkers of synucleinopathy, and (3) skin punch biopsy and lumbar puncture have comparable mild adverse effects, tolerance, and acceptance. RT-QuIC in the skin or CSF might represent a patient selection strategy for future neuroprotective trials targeting AS in IRBD. This study provides Class III evidence that RT-QuIC-detected AS in the skin and CSF distinguishes patients with IRBD from controls.
Sections du résumé
BACKGROUND AND OBJECTIVES
Real-time quaking-induced conversion (RT-QuIC) assay detects misfolded α-synuclein (AS) in the skin and CSF of patients with the synucleinopathies Parkinson disease and dementia with Lewy bodies. Isolated REM sleep behavior disorder (IRBD) constitutes the prodromal stage of these synucleinopathies. We aimed to compare the ability of RT-QuIC to identify AS in the skin and CSF of patients with IRBD.
METHODS
This was a cross-sectional study where consecutive patients with polysomnographic-confirmed IRBD and age-matched controls without RBD underwent skin biopsy and lumbar puncture the same day. Three-millimeter skin punch biopsies were obtained bilaterally in the cervical region from dorsal C7 and C8 dermatomes and in distal legs. RT-QuIC assessed AS in these 6 skin sites and the CSF.
RESULTS
We recruited 91 patients with IRBD and 41 controls. In the skin, sensitivity to detect AS was 76.9% (95% CI 66.9-85.1), specificity 97.6% (95% CI 87.1-99.9) positive predictive value 98.6% (95% CI 91.0-99.8), negative predictive value 65.6% (95% CI 56.6-73.6), and accuracy 83.3% (95% CI 75.9-89.3). In the CSF, the sensitivity was 75.0% (95% CI 64.6-83.6), the specificity was 97.5% (95% CI 86.8-99.9), the positive predictive value was 98.5% (95% CI 90.5-99.8), the negative predictive value was 63.9% (95% CI 55.2-71.9), and the accuracy was 82.0% (95% CI 74.3-88.3). Results in the skin and CSF samples showed 99.2% agreement. Compared with negative patients, RT-QuIC AS-positive patients had a higher likelihood ratio of prodromal Parkinson disease (
DISCUSSION
Our study in IRBD shows that (1) RT-QuIC detects AS in the skin and CSF with similar high sensitivity, specificity, and agreement, (2) AS RT-QuIC positivity is associated with supportive features and biomarkers of synucleinopathy, and (3) skin punch biopsy and lumbar puncture have comparable mild adverse effects, tolerance, and acceptance. RT-QuIC in the skin or CSF might represent a patient selection strategy for future neuroprotective trials targeting AS in IRBD.
CLASSIFICATION OF EVIDENCE
This study provides Class III evidence that RT-QuIC-detected AS in the skin and CSF distinguishes patients with IRBD from controls.
Identifiants
pubmed: 36931726
pii: WNL.0000000000207147
doi: 10.1212/WNL.0000000000207147
pmc: PMC10159765
doi:
Substances chimiques
alpha-Synuclein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1944-e1954Informations de copyright
© 2023 American Academy of Neurology.
Références
Sleep Med. 2017 Dec;40:116-121
pubmed: 29042180
Neurology. 2009 Dec 1;73(22):1914-22
pubmed: 19949037
Lancet Neurol. 2021 Mar;20(3):203-212
pubmed: 33609478
Mov Disord. 2020 Dec;35(12):2230-2239
pubmed: 32960470
Lancet Neurol. 2013 May;12(5):443-53
pubmed: 23562390
Neurologia (Engl Ed). 2019 Jul - Aug;34(6):376-385
pubmed: 28364958
Lancet Neurol. 2016 Jun;15(7):708-718
pubmed: 27039162
Mov Disord. 2019 Apr;34(4):536-544
pubmed: 30840785
Ann Neurol. 2012 Aug;72(2):278-85
pubmed: 22926858
Brain. 2022 Apr 18;145(2):584-595
pubmed: 34894214
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
Sleep. 2021 Dec 10;44(12):
pubmed: 34244806
Parkinsonism Relat Disord. 2022 Jun;99:33-41
pubmed: 35594661
Ann Clin Transl Neurol. 2020 Apr;7(4):559-564
pubmed: 32141717
Acta Neuropathol. 2020 Jul;140(1):49-62
pubmed: 32342188
Sleep. 1991 Dec;14(6):540-5
pubmed: 1798888
Sleep Med. 2018 Dec;52:14-17
pubmed: 30195197
Acta Neuropathol Commun. 2018 Feb 9;6(1):7
pubmed: 29422107
Neurology. 2017 Jul 4;89(1):88-100
pubmed: 28592453
Brain. 2021 May 7;144(4):1118-1126
pubmed: 33855335
Sleep Med. 2013 Aug;14(8):754-62
pubmed: 23474058
Eur J Neurol. 2010 Jul;17(7):903-12, e44-9
pubmed: 20642627
J Alzheimers Dis. 2014;39(4):719-26
pubmed: 24254700
Lancet Neurol. 2016 Apr;15(4):405-19
pubmed: 26971662
Acta Neuropathol. 2017 Apr;133(4):535-545
pubmed: 28180961
Cell Tissue Res. 2018 Jul;373(1):183-193
pubmed: 29185072
Trends Mol Med. 2012 May;18(5):248-55
pubmed: 22503115
Mov Disord. 2008 Nov 15;23(15):2129-70
pubmed: 19025984
Mov Disord. 2021 Apr;36(4):895-904
pubmed: 33232556
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
Parkinsonism Relat Disord. 2013 Jun;19(6):600-4
pubmed: 23529022
Clin Auton Res. 2011 Apr;21(2):69-72
pubmed: 21431947
Ann Clin Transl Neurol. 2019 Oct;6(10):2120-2126
pubmed: 31599499
Neurology. 2021 Aug 31;97(9):e930-e940
pubmed: 34210822
Parkinsonism Relat Disord. 2022 Jun;99:58-61
pubmed: 35605512
Acta Neuropathol Commun. 2020 Jul 25;8(1):117
pubmed: 32711575
Gastroenterology. 2006 Apr;130(5):1480-91
pubmed: 16678561
Mov Disord. 2021 Sep;36(9):2173-2177
pubmed: 34002890
Neurology. 2017 May 30;88(22):2128-2131
pubmed: 28468843
Ann Clin Transl Neurol. 2016 Aug 28;3(10):812-818
pubmed: 27752516
Eur J Nucl Med Mol Imaging. 2020 Jul;47(8):1885-1912
pubmed: 32388612
NPJ Parkinsons Dis. 2021 Oct 11;7(1):93
pubmed: 34635674
Sleep. 2018 Aug 1;41(8):
pubmed: 29790977
Nat Rev Neurol. 2018 Jan;14(1):40-55
pubmed: 29170501
Mov Disord. 2019 Oct;34(10):1464-1470
pubmed: 31412427
Neurology. 2015 Nov 17;85(20):1761-8
pubmed: 26475692
Brain. 2019 Mar 1;142(3):744-759
pubmed: 30789229
Ann Neurol. 2017 Sep;82(3):419-428
pubmed: 28833467